Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform ...
GlobalData on MSN10d
Longboard commences Phase III trial of bexicaserin for DEEs seizure treatmentLongboard Pharmaceuticals has commenced the Phase III DEEp OCEAN Study of its investigational oral drug bexicaserin for ...
HT2C functional selectivity and Phase 1 clinical data - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Inc. (NASDAQ: DRUG), a ...
Enveric’s drug discovery engine has also uncovered molecules demonstrating enhanced preference for 5-HT2C receptors. “Included in our portfolio are several molecules, protected by issued ...
The poster is available on www.brightmindsbio.com. BMB-201, a selective 5-HT2A/2C receptor agonist, was designed to harness the analgesic potential of serotonin modulation without the ...
as well as targeted serotonin 5-HT1A and 5-HT2C receptor agonists. “The granting of this patent in support of our CYB005 phenethylamines program reinforces our commitment to expanding the ...
Enveric’s drug discovery engine has also uncovered molecules demonstrating enhanced preference for 5-HT2C receptors. “Included in our portfolio are several molecules, protected by issued patent claims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback